Immutep ( ASX: IMM ) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at different phases of clinical trials. But its lead product candidate is Eftilagimod Alpha (Efti), a recombinant protein that is in phase 2b clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. …
